---
title: "Pharmaceutical Excipients For Injection Market, Global Outlook and Forecast 2025-2032"
datePublished: Thu Nov 06 2025 19:00:47 GMT+0000 (Coordinated Universal Time)
cuid: cmhnsl5e1000002jp8rr92hu3
slug: pharmaceutical-excipients-for-injection-market-global-outlook-and-forecast-2025-2032-1-1-1

---

# Pharmaceutical Excipients For Injection Market, Global Outlook and Forecast 2025-2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global pharmaceutical excipients for injection market size was valued at <strong>USD 1533 million in 2024</strong> and is projected to reach <strong>USD 2292 million by 2032</strong>, growing at a <strong>CAGR of 6.1%</strong> during the forecast period.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/289981/pharmaceutical-excipients-for-injection-market">
            https://www.24chemicalresearch.com/download-sample/289981/pharmaceutical-excipients-for-injection-market</a></b></div><br><p>
</p><p>Pharmaceutical excipients for injection are inactive ingredients in sterile drug formulations that ensure stability, solubility, and safety of injectable medications. These specialized excipients include solvents, solubilizers, pH adjusters, and antioxidants which must meet stringent regulatory standards because they directly enter systemic circulation. Compared to oral dosage excipients, injectable-grade materials require higher purity levels and specialized manufacturing processes to avoid adverse reactions.</p><p>
</p><p>Market growth is driven by increasing biologics production - projected to reach USD 381 billion in 2022 - and rising demand for parenteral drug delivery systems. However, the industry faces challenges including complex sterilization requirements and supply chain vulnerabilities exposed during COVID-19. Key players like Dow, Croda, and NOF are investing in novel excipient development, particularly for mRNA vaccines and high-concentration biologics where stability is critical. Recent regulatory harmonization efforts by ICH and USP are expected to further streamline excipient qualification processes globally.</p><p>
<img alt="Global pharmaceutical excipients for injection market outlook- 24chemicalresearch" src="https://www.24chemicalresearch.com/assets/report-images/download_-_2025-07-25T145338_417.webp" style="height:480px; width:750px"></p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Rising Biologics Development Accelerates Demand for High-Purity Excipients</strong></p><p>
</p><p>The biologics market, valued at over $380 billion globally, is creating unprecedented demand for specialized pharmaceutical excipients for injections. Unlike traditional small-molecule drugs, biologic formulations require excipients that maintain protein stability, prevent aggregation, and ensure proper drug delivery. This is driving innovation in excipient technologies, particularly for monoclonal antibodies, recombinant proteins, and mRNA vaccines. The market is responding with advanced solubility enhancers and stabilizers specifically designed for sensitive biologics, with manufacturers increasingly focusing on meeting stringent regulatory requirements for these critical components.</p><p>
</p><p style="text-align:center"><strong>Pandemic Preparedness Investments Fuel Sustained Market Growth</strong></p><p>
</p><p>Global health initiatives following the COVID-19 pandemic have created lasting impacts on the injectable excipients market. Governments worldwide have committed billions to expand vaccine manufacturing capacity and develop rapid-response platforms. This has led to increased demand for specialized excipients used in mRNA vaccines and other novel vaccine technologies. Production capacities for critical excipients like polyethylene glycol (PEG) and lipid nanoparticles have expanded significantly, with annual growth rates exceeding 15% in these segments. The emphasis on pandemic preparedness ensures these investments will continue driving market expansion throughout the forecast period.</p><p>
</p><p style="text-align:center"><strong>Advancements in Drug Delivery Technologies Create New Application Areas</strong></p><p>
</p><p>Innovations in controlled-release injectables and biocompatible formulations are opening new opportunities for excipient manufacturers. Long-acting injectable (LAI) formulations, which maintain therapeutic drug levels for weeks or months, require specialized excipients that enable gradual drug release while maintaining stability. The market has responded with novel polymer-based excipient systems that meet these demanding requirements. Additionally, the development of targeted drug delivery systems demands excipients that can facilitate site-specific release, creating opportunities for advanced functional excipients in oncology and other specialized therapeutic areas.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Requirements Increase Development Costs and Timelines</strong></p><p>
</p><p>Injectable excipients face significantly more rigorous regulatory scrutiny than those for oral formulations due to their direct entry into the bloodstream. The approval process for new excipients can take 5-7 years and cost upwards of $20 million, creating substantial barriers to market entry. Regulatory agencies require comprehensive safety data, including extensive toxicology studies and documentation of manufacturing processes. These requirements lead to higher development costs that are often passed on to end-users, potentially limiting adoption in cost-sensitive markets.</p><p>
</p><p style="text-align:center"><strong>Supply Chain Vulnerabilities Impact Market Stability</strong></p><p>
</p><p>The global pharmaceutical excipients market remains vulnerable to supply chain disruptions, as demonstrated during recent geopolitical events and the pandemic. Many critical excipients rely on limited production facilities, with over 60% of certain specialty excipients manufactured at just two or three sites worldwide. This concentration creates risks of shortages and price volatility. Additionally, some excipient materials require specialized storage and transportation conditions, further complicating supply chain management and increasing costs for manufacturers.</p><p>
</p><p style="text-align:center"><strong>Growing Preference for Non-Injectable Alternatives Limits Growth Potential</strong></p><p>
</p><p>While injectables remain essential for many therapies, numerous drug developers are investigating alternative administration routes to improve patient compliance. Oral biologics, transdermal patches, and inhalation technologies are becoming increasingly viable for some treatments that previously required injection. This trend could reduce demand for injectable formulations in certain therapeutic areas, particularly for chronic conditions requiring frequent dosing. However, many biologics and emergency medications will continue to require injectable formulations, ensuring sustained demand for high-quality excipients.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Emerging Markets Present Significant Untapped Potential for Growth</strong></p><p>
</p><p>Developing economies in Asia, Latin America, and Africa represent the fastest-growing markets for pharmaceutical excipients, with annual growth rates exceeding 10% in many regions. As these countries expand their healthcare infrastructure and increase access to injectable medicines, demand for high-quality excipients is growing rapidly. Local manufacturers are investing in production capabilities, while global players are establishing regional manufacturing and distribution networks. The increasing prevalence of chronic diseases in these markets and government initiatives to strengthen domestic pharmaceutical production further enhance growth prospects.</p><p>
</p><p style="text-align:center"><strong>Customized Excipient Solutions for Advanced Therapies Create New Revenue Streams</strong></p><p>
</p><p>The rapid development of cell and gene therapies presents opportunities for excipient manufacturers to develop specialized formulation solutions. These advanced therapies require excipients that can maintain cell viability, protect genetic material during delivery, and minimize immune reactions. The market is responding with novel cryoprotectants, nucleic acid stabilizers, and other specialized excipients tailored to these cutting-edge applications. With the cell and gene therapy market projected to exceed $30 billion by 2030, excipient manufacturers are investing heavily in this high-value segment.</p><p>
</p><p style="text-align:center"><strong>Sustainability Initiatives Drive Innovation in Green Excipient Technologies</strong></p><p>
</p><p>Growing environmental concerns are prompting pharmaceutical companies to seek sustainable excipient options. Manufacturers are developing bio-based alternatives to petroleum-derived excipients, plant-sourced stabilizers, and other eco-friendly formulation components. Regulatory agencies are increasingly encouraging these developments through green chemistry initiatives. While comprising a small portion of the market today, sustainable excipients could account for over 20% of new product launches by 2030, creating opportunities for innovators in this space.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Technical Complexities in Formulation Development Strain Resources</strong></p><p>
</p><p>Developing stable, effective injectable formulations presents significant technical challenges that impact excipient selection and use. Many biologic drugs require precise combinations of excipients to maintain stability, often with narrow acceptable ranges for pH, tonicity, and other parameters. These formulation complexities increase development costs and timelines, with many projects requiring extensive experimentation to identify optimal excipient combinations. Additionally, the interaction between excipients and primary packaging materials adds another layer of complexity to formulation development.</p><p>
</p><p style="text-align:center"><strong>Patented Formulation Technologies Constrain Excipient Innovation</strong></p><p>
</p><p>Many advanced drug formulations incorporate patented excipient combinations and manufacturing processes, creating barriers to market entry for generic competitors. While this drives innovation, it also limits the adoption of newer, potentially superior excipient technologies by branded drug manufacturers reluctant to modify successful formulations. The complex intellectual property landscape surrounding drug-excipient combinations requires careful navigation by both excipient suppliers and pharmaceutical manufacturers.</p><p>
</p><p style="text-align:center"><strong>Quality Control Requirements Escalate Production Costs</strong></p><p>
</p><p>Injectable excipients must meet exceptionally high purity standards, with stringent limits on endotoxins, particulates, and other contaminants. Maintaining these standards requires significant investment in quality control infrastructure and specialized manufacturing processes. The cost of quality control testing alone can account for 15-20% of total production costs for some high-purity excipients. These requirements create substantial barriers to entry for new market participants while putting upward pressure on prices for established manufacturers.</p><p>
<strong>MARKET TRENDS</strong></p><p>
<strong>Rising Demand for Biologics and Complex Formulations Driving Market Growth</strong></p><p>
</p><p>Global pharmaceutical excipients for injection market is witnessing robust expansion, projected to grow from $1.53 billion in 2024 to $2.29 billion by 2032, at a 6.1% CAGR. This surge is primarily fueled by the escalating demand for biologics and complex injectable formulations. With biologics accounting for $381 billion of the global pharmaceutical market in 2022, excipients play a critical role in ensuring the stability and efficacy of these sensitive formulations. Recent advancements in lyophilization technologies and sterile manufacturing processes have enabled pharmaceutical companies to develop more sophisticated injectable products, particularly for oncology and autoimmune therapies. The market is further propelled by regulatory approvals of novel excipients specifically designed for high-concentration monoclonal antibodies and mRNA-based vaccines, addressing previously unmet formulation challenges.</p><p>
<strong>Other Trends</strong></p><p>
</p><p style="text-align:center"><strong>Increased Focus on Patient-Centric Formulations</strong></p><p>
</p><p>The shift toward patient-centric drug development is reshaping excipient requirements for injectables. Formulators are increasingly adopting reduced-volume formulations and ready-to-use systems to enhance patient compliance, particularly in chronic disease management. This trend is evident in the growing popularity of auto-injectors and prefilled syringes, which represented over 35% of the total injectable drug delivery market in recent years. Excipients enabling improved solubility and reduced injection-site reactions are gaining prominence, with innovations like hyaluronidase-based permeation enhancers showing significant clinical benefits. The market is also seeing increased demand for preservative-free excipient systems to minimize adverse effects while maintaining sterility assurance.</p><p>
<strong>Technological Advancements in Excipient Development</strong></p><p>
</p><p>Breakthroughs in nanotechnology and molecular engineering are revolutionizing injectable excipients. Novel lipid-based excipients developed for mRNA vaccine delivery during the COVID-19 pandemic have demonstrated remarkable potential for broader applications, including gene therapies and targeted drug delivery systems. The market is witnessing increased R&amp;D investment in smart excipients capable of pH-responsive release and targeted biodistribution, with several candidates in late-stage clinical trials. Concurrently, advances in analytical characterization techniques such as high-resolution mass spectrometry allow for more precise quality control of excipient purity – critical for meeting stringent pharmacopeial requirements for injectables. These technological improvements are enabling formulators to overcome longstanding challenges in peptide stabilization and protein aggregation, particularly for biosimilar development.</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Innovation and Strategic Expansion Drive Market Competition</strong></p><p>
</p><p>Global pharmaceutical excipients for injection market features a dynamic competitive environment with both <strong>multinational corporations</strong> and <strong>regional specialists</strong> vying for market share. <strong>Dow Chemical Company</strong> leads the segment, leveraging its extensive chemical manufacturing expertise and global distribution network to maintain <strong>approximately 18% revenue share</strong> in 2024. The company's dominance stems from its diversified excipient portfolio and strategic investments in high-purity formulations required for sterile injectables.</p><p>
</p><p>Japanese firm <strong>Nippon Fine Chemical</strong> has emerged as a key competitor, particularly in the Asian markets, holding an estimated <strong>12% market share</strong> last year. Their growth strategy centers on specialized solubilizers and pH adjusters - critical components for biologics formulations. Similarly, <strong>Croda International</strong> has strengthened its position through targeted acquisitions, including its 2023 purchase of a Spanish excipient manufacturer to bolster European market penetration.</p><p>
</p><p>Recent industry trends show manufacturers actively pursuing <strong>three strategic priorities</strong>: expanding GMP-certified production facilities, developing novel functional excipients for mRNA therapeutics, and forming partnerships with biopharma companies for custom formulation solutions. This focus on specialization has allowed mid-sized players like <strong>Pfanstiehl Laboratories</strong> to compete effectively despite the presence of industry giants, particularly in niche segments such as lyophilization stabilizers.</p><p>
</p><p>Meanwhile, Chinese manufacturers including <strong>Nanjing Well Pharmaceutical</strong> and <strong>Jiangsu Poly Pharmaceutical</strong> are rapidly gaining traction, supported by government initiatives to localize pharmaceutical supply chains. These companies are investing heavily in technology upgrades to meet increasingly stringent international quality standards, positioning themselves as cost-effective alternatives to Western suppliers.</p><p>
<strong>List of Leading Pharmaceutical Excipient Suppliers</strong></p><p>
</p><p>Dow Chemical Company (U.S.)</p><p><strong>Nippon Fine Chemical (Japan)</strong></p><p>Nanjing Well Pharmaceutical (China)</p><p>Jiangsu Maxim Biological (China)</p><p><strong>NOF Corporation (Japan)</strong></p><p><strong>Croda International (UK)</strong></p><p>Jiangsu Poly Pharmaceutical (China)</p><p>Er Kang Pharmaceutical (China)</p><p>Guangzhou Hanfang Pharmaceutical (China)</p><p><strong>Pfanstiehl Laboratories (U.S.)</strong></p><p>Xi'an Libang Pharmaceutical (China)</p><p>Zhejiang Tianyushan Medicinal Oil (China)</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Solvents Segment Leads Due to Critical Role in Drug Formulation Stability</strong></p><p>
</p><p>The market is segmented based on type into:</p><p>
</p><p>Solvents</p><p>
</p><p>Solubilizers</p><p>
</p><p>pH Adjusters</p><p>
</p><p>Antioxidants</p><p>
</p><p>Others</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Chemical Injections Dominate Market Share Owing to Widespread Use in Modern Therapeutics</strong></p><p>
</p><p>The market is segmented based on application into:</p><p>
</p><p>Chemical Injections</p><p>Traditional Chinese Medicine Injections</p><p>Biologic Injections</p><p>Vaccines</p><p>Others</p><p>
<strong>By Functionality</strong></p><p>
</p><p><strong>Stabilizing Agents Witness High Demand for Maintaining Drug Integrity</strong></p><p>
</p><p>The market is segmented based on functionality into:</p><p>
</p><p>Stabilizing Agents</p><p>Bulking Agents</p><p>Tonicity Agents</p><p>Preservatives</p><p>Others</p><p>
<strong>By End User</strong></p><p>
</p><p><strong>Pharmaceutical Manufacturers Hold Majority Share as Primary Formulators</strong></p><p>
</p><p>The market is segmented based on end user into:</p><p>
</p><p>Pharmaceutical Manufacturers</p><p>Contract Research Organizations</p><p>Academic Research Institutes</p><p>Biotechnology Companies</p><p>
<strong>Regional Analysis: Pharmaceutical Excipients For Injection Market</strong></p><p>
</p><p><strong>North America</strong></p><p>
</p><p>The North American market for pharmaceutical excipients used in injectable formulations is characterized by stringent regulatory oversight from the U.S. FDA and Health Canada, necessitating compliance with Good Manufacturing Practices (GMP) and harmonized pharmacopeial standards. This region accounts for a significant share of the global market due to the high demand for biologics and sterile medications, particularly in the U.S., where drug development pipelines increasingly focus on injectable therapies. Companies operating here emphasize high-purity excipients with minimal endotoxin levels, driven by the need for precision in drug delivery. The shift toward biosimilars and complex generics is further accelerating demand for specialized excipients in parenteral applications. While costs are higher due to regulatory compliance, the region benefits from established pharmaceutical manufacturing clusters in states like New Jersey and Massachusetts.</p><p>
</p><p><strong>Europe</strong></p><p>
</p><p>Europe maintains strict quality controls through the European Pharmacopoeia and EMA guidelines, creating a robust framework for excipient safety. Countries such as Germany, France, and Switzerland are key hubs for innovative biologics manufacturing, driving demand for excipients with enhanced stability and solubility profiles. The region’s focus on sustainability and reduced excipient variability has led to advancements in biodegradable polymers and lipid-based systems for controlled drug release. Patented excipient formulations are increasingly adopted to meet the requirements of novel biologic therapies. Despite Brexit’s impact on supply chains, the EU’s unified regulatory framework supports market stability, though price sensitivity in Eastern Europe remains a challenge.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
</p><p>As the fastest-growing regional market, Asia-Pacific is propelled by expanding clinical trial activities and government-led pharmaceutical initiatives, especially in China and India. Local manufacturers are scaling up GMP-compliant excipient production to reduce reliance on imports, with China emerging as a key supplier of cost-effective alternatives. Japan’s emphasis on high-quality specialty excipients for biologics contrasts with India’s focus on generics. While affordability drives demand for conventional excipients, rising R&amp;D investment is fostering innovation. Challenges include fragmented regulations and inconsistent raw material quality in Southeast Asia, though harmonization efforts under ASEAN are gradually improving standards.</p><p>
</p><p><strong>South America</strong></p><p>
</p><p>The market here is developing slowly due to economic instability, yet Brazil and Argentina are making progress through public-private partnerships to modernize drug production. Local regulators are adopting stricter pharmacopeial standards, though supply chain bottlenecks and limited domestic excipient producers hinder growth. Demand is concentrated in generic injectables, with increasing interest in prefilled syringes driving niche opportunities for excipients like viscosity modifiers. Currency fluctuations and reliance on imports from North America or Europe create cost pressures, but regional trade agreements may alleviate this over time.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
</p><p>This region represents an emerging opportunity, with Saudi Arabia, UAE, and South Africa leading investment in localized pharmaceutical manufacturing to reduce import dependence. Vaccine production initiatives post-COVID-19 are boosting demand for sterile excipients, while Gulf Cooperation Council (GCC) harmonization efforts aim to streamline approvals. Africa’s market remains constrained by limited infrastructure, though multinationals are exploring partnerships to serve unmet needs in oncology and infectious disease treatments. The lack of regional excipient suppliers results in higher logistics costs, but long-term potential is tied to healthcare expansion programs.</p><p>
<strong>Report Scope</strong></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Pharmaceutical Excipients For Injection, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Pharmaceutical Excipients For Injection manufacturers and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Pharmaceutical Excipients For Injection Market?</strong></p><p>
</p><p>-&gt; Global Pharmaceutical Excipients For Injection market was valued at USD 1533 million in 2024 and is projected to reach USD 2292 million by 2032, growing at a CAGR of 6.1% during the forecast period.</p><p>
<strong>Which key companies operate in Global Pharmaceutical Excipients For Injection Market?</strong></p><p>
</p><p>-&gt; Key players include Dow, Nippon Fine Chemical, Nanjing Well Pharmaceutical, Jiangsu Maxim Biological, NOF, Croda, Jiangsu Poly Pharmaceutical, Er Kang Pharmaceutical, Guangzhou Hanfang Pharmaceutical, Pfanstiehl, Xi'an Libang Pharmaceutical, and Zhejiang Tianyushan Medicinal Oil, among others.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include rising pharmaceutical production, increasing demand for biologics, stringent regulatory requirements for sterile formulations, and technological advancements in drug delivery systems.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p>-&gt; Asia-Pacific is the fastest-growing region, driven by expanding pharmaceutical manufacturing in China and India, while North America maintains technological leadership in excipient development.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include development of multifunctional excipients, increasing adoption of natural excipients, and growing focus on biosimilars and sterile injectable formulations.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/289981/pharmaceutical-excipients-for-injection-market">
            https://www.24chemicalresearch.com/reports/289981/pharmaceutical-excipients-for-injection-market</a></b></div><br>
            <b>Table of Content:</b><p>Table of Contents<br />
1 Research Methodology and Statistical Scope<br />
1.1 Market Definition and Statistical Scope of Pharmaceutical Excipients For Injection<br />
1.2 Key Market Segments<br />
1.2.1 Pharmaceutical Excipients For Injection Segment by Type<br />
1.2.2 Pharmaceutical Excipients For Injection Segment by Application<br />
1.3 Methodology & Sources of Information<br />
1.3.1 Research Methodology<br />
1.3.2 Research Process<br />
1.3.3 Market Breakdown and Data Triangulation<br />
1.3.4 Base Year<br />
1.3.5 Report Assumptions & Caveats<br />
2 Pharmaceutical Excipients For Injection Market Overview<br />
2.1 Global Market Overview<br />
2.1.1 Global Pharmaceutical Excipients For Injection Market Size (M USD) Estimates and Forecasts (2019-2032)<br />
2.1.2 Global Pharmaceutical Excipients For Injection Sales Estimates and Forecasts (2019-2032)<br />
2.2 Market Segment Executive Summary<br />
2.3 Global Market Size by Region<br />
3 Pharmaceutical Excipients For Injection Market Competitive Landscape<br />
3.1 Global Pharmaceutical Excipients For Injection Sales by Manufacturers (2019-2024)<br />
3.2 Global Pharmaceutical Excipients For Injection Revenue Market Share by Manufacturers (2019-2024)<br />
3.3 Pharmaceutical Excipients For Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)<br />
3.4 Global Pharmaceutical Excipients For Injection Average Price by Manufacturers (2019-2024)<br />
3.5 Manufacturers Pharmaceutical Excipients For Injection Sales Sites, Area Served, Product Type<br />
3.6 Pharmaceutical Excipients For Injection Market Competitive Situation and Trends<br />
3.6.1 Pharmac</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/289981/pharmaceutical-excipients-for-injection-market">
            https://www.24chemicalresearch.com/reports/289981/pharmaceutical-excipients-for-injection-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>